Frontiers in Immunology (Jun 2022)
Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis
- Alexandra Serris,
- Amani Ouedrani,
- Amani Ouedrani,
- Fabrice Uhel,
- Marianne Gazzano,
- Vincent Bedarida,
- Claire Rouzaud,
- Marie-Elisabeth Bougnoux,
- Jean-Herlé Raphalen,
- Sylvain Poirée,
- Olivier Lambotte,
- Olivier Lambotte,
- Guillaume Martin-Blondel,
- Guillaume Martin-Blondel,
- Fanny Lanternier,
- Fanny Lanternier
Affiliations
- Alexandra Serris
- Centre for Infectious Diseases and Tropical Medicine, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique –Hôpitaux de Paris, Université de Paris, Paris, France
- Amani Ouedrani
- Immunology Laboratory, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique –Hôpitaux de Paris, Université de Paris, Paris, France
- Amani Ouedrani
- Immunoregulation and Immunopathology, Département Immunologie UMR_S1151 UMR8253 Institut Necker Enfants Malades, Université de Paris, Paris, France
- Fabrice Uhel
- Intensive Care Medicine, Hôpital Louis Mourier, Assistance Publique –Hôpitaux de Paris, Colombes, France
- Marianne Gazzano
- Department of Immunologie, Hôpitaux universitaires Pitié Salpêtrière-Charles Foix, Assistance Publique –Hôpitaux de Paris, Paris, France
- Vincent Bedarida
- Otolaryngology-Head and Neck Surgery Department, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
- Claire Rouzaud
- Centre for Infectious Diseases and Tropical Medicine, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique –Hôpitaux de Paris, Université de Paris, Paris, France
- Marie-Elisabeth Bougnoux
- Parasitology-Mycology Laboratory, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique –Hôpitaux de Paris, Paris, France
- Jean-Herlé Raphalen
- Intensive Care Medicine, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique –Hôpitaux de Paris, Université de Paris, Paris, France
- Sylvain Poirée
- Department of Adult radiology, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique –Hôpitaux de Paris, Paris, France
- Olivier Lambotte
- 0Service de Médecine Interne Immunologie Clinique, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, Le Kremlin Bicêtre, France
- Olivier Lambotte
- 1Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IDMIT/IMVA-HB), UMR1184, Université Paris-Saclay, Inserm, CEA, Le Kremlin Bicêtre, France
- Guillaume Martin-Blondel
- 2Service des Maladies Infectieuses et Tropicales, CHU de Toulouse, Université Toulouse III, Toulouse, France
- Guillaume Martin-Blondel
- 3Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse, France
- Fanny Lanternier
- Centre for Infectious Diseases and Tropical Medicine, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique –Hôpitaux de Paris, Université de Paris, Paris, France
- Fanny Lanternier
- 4Molecular Mycology Unit, National Reference Centre for Invasive Mycoses and Antifungals, UMR 2000, Institut Pasteur, CNRS, Université de Paris, Paris, France
- DOI
- https://doi.org/10.3389/fimmu.2022.900522
- Journal volume & issue
-
Vol. 13
Abstract
Invasive fungal diseases (IFD) still cause substantial morbidity and mortality, and new therapeutic approaches are urgently needed. Recent data suggest a benefit of checkpoint inhibitors (ICI). We report the case of a diabetic patient with refractory IFD following a SARSCoV-2 infection treated by ICI and interferon-gamma associated with antifungal treatment.
Keywords
- invasive fungal disease
- anti-PD 1
- cerebral mucormycosis
- covid-associated pulmonary aspergillosis
- immunotherapy
